FOLD Amicus Therapeutics, Inc.

8.26
-0.15  -2%
Previous Close 8.41
Open 8.41
Price To book 3.86
Market Cap 1.18B
Shares 142,916,000
Volume 2,774,286
Short Ratio 10.04
Av. Daily Volume 2,705,350

SEC filingsSee all SEC filings

  1. 8-K - Current report 17859754
  2. 8-K - Current report 17856390
  3. 8-K - Current report 17851049
  4. 8-K - Current report 17841453
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825077

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
Migalastat HCl monotherapy (012)
Fabry Disease
Phase 3 enrollment completed April 3, 2017 with top-line data due 3Q 2017.
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 additional data released February 15, 2017. Further data released May 15, 2017.
ATB200
Pompe Disease

Latest News

  1. Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study
  2. Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics
  3. Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study
  4. Edited Transcript of FOLD earnings conference call or presentation 9-May-17 12:30pm GMT
  5. Amicus Therapeutics to Present at Two Upcoming Investor Conferences
  6. ETFs with exposure to Amicus Therapeutics, Inc. : May 9, 2017
  7. Amicus Therapeutics reports 1Q loss
  8. Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call
  9. Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
  10. Amicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : May 8, 2017
  11. Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : May 5, 2017
  12. Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
  13. Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France
  14. Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
  15. Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
  16. Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics
  17. Are These 2 Biotechs Diamonds in the Rough?
  18. Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy
  19. Harry Boxer’s six biotechnology stocks to watch
  20. Four biotech stocks surging on optimism about drug trials, product launches

SEC Filings

  1. 8-K - Current report 17859754
  2. 8-K - Current report 17856390
  3. 8-K - Current report 17851049
  4. 8-K - Current report 17841453
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825077
  6. 8-K - Current report 17824700
  7. 8-K - Current report 17793087
  8. DEF 14A - Other definitive proxy statements 17790829
  9. 8-K - Current report 17732320
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 17685717